Click here for slides on this topic


EMPA-REG OUTCOME

The cardiovascular outcomes trial (CVOT) for the SGLT2 inhibitor, empagliflozin. The study randomized 7,020 subjects with type 2 diabetes and established CVD who were on standard care to empagliflozin 10 mg, empagliflozin 25 mg, or placebo. Follow-up occurred over a median of 3.1 years.
The following content matched the glossary term: EMPA-REG OUTCOME

NDEI.org Expert Commentary Ed Horton, MD, on EMPA-REG OUTCOME Results

Top

Ed Horton, MD, discusses EMPA-REG OUTCOME results: SGLT2 inhibitor, empagliflozin, cuts CV deaths in high-risk type 2 diabetes patients

NDEI.org Expert Commentary Vivian Fonseca, MD, on EMPA-REG OUTCOME: Empagliflozin Cuts CV Deaths

Top

Vivian Fonseca, MD, discusses the impact of EMPA-REG OUTCOME; SGLT2 inhibitor, empagliflozin, reduced cardiovascular deaths in high-risk type 2 diabetes patients

Empagliflozin Cuts Cardiovascular Deaths in Landmark Trial

Top

The SGLT2 inhibitor, empagliflozin, reduces cardiovascular deaths in the EMPA-REG OUTCOME trial. Includes expert commentary.



Slide Library Results

Search Results for: EMPA-REG OUTCOME Slides Found: 8
EMPA-REG OUTCOME Empagliflozin CV Death Reduced Type 2 Diabetes | NDEI
Empagliflozin Reduces Death Type 2 Diabetes EMPA-REG OUTCOME EASD | NDEI
EMPA-REG OUTCOME Empagliflozin Heart Failure Type 2 Diabetes EASD | NDEI
EMPA-REG OUTCOME Empagliflozin A1C High-Risk Type 2 Diabetes | NDEI
Empagliflozin Safety Adverse Events Type 2 Diabetes EMPA-REG OUTCOME | NDEI
EMPA-REG OUTCOME Design Empagliflozin SGLT2 Type 2 Diabetes | NDEI
Empagliflozin Reduces Kidney Disease in EMPA-REG OUTCOME CVOT | NDEI
Empagliflozin Renal Outcomes in EMPA-REG OUTCOME CVOT | NDEI